Context Therapeutics Inc. announced on March 26, 2025, that a poster regarding its clinical asset, CT-95, a mesothelin (MSLN) x CD3 T cell engager, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting is scheduled for April 25-30, 2025, in Chicago, IL.
The presentation will highlight data supporting the selection of the first-in-human dose of CT-95, utilizing the minimal anticipated biological effect level (MABEL) approach. This approach is required for immune agonist drugs and indicates the dose level expected to lead to a minimal biological effect in humans.
The weight of evidence from these data supports the safety of the proposed clinical starting dose of 0.1 μg/kg for CT-95. This information is crucial as the company prepares to advance CT-95 into clinical trials for mesothelin-expressing cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.